• Ying Yi, Ziyi Hu, Renliang Li, Lisha Chen, Hengyi Zhang, Hong Li, Mengwen Wu, and Wanting Liu.
• Jiangxi University of Traditional Chinese Medicine.
• Medicine (Baltimore). 2021 Apr 23; 100 (16): e25607e25607.

BackgroundGastric precancerous lesion (GPL) is a necessary stage in the occurrence and development of gastric cancer. At present, the incidence of gastric cancer is increasing year by year. It is important to prevent and control gastric cancer through early detection and intervention. Banxia Xiexin Decoction (BXD) has a good effect in improving symptoms, reducing inflammation, promoting the repair of gastric mucosa, reversing its atrophy and intestinal metaplasia. BXD may be a foreground choice for the treatment of GPL.MethodsRandomized controlled trials of BXD for GPL will be searched in the relevant database, including PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Biomedical Literature Database (CBM), and Chinese Scientific Journal Database (VIP database). The studies of electronic searches will be exported to EndNote V.9.1 software. We will run meta-analyses using the Review Manager (RevMan) V.5.3 software. Any disagreement will be solved in consultation with a third reviewer.ResultsOur study aims to explore the efficacy of BXD for GPL and to provide up-to-date evidence for clinical of GPL.ConclusionThe conclusion of this study will provide evidence for the efficacy of BXD on GPL.Inplasy Registration NumberINPLASY 202130102.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

36 keywords...

hide…